Foretinib

Foretinib
IUPAC name

N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names

XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
CAS number 849217-64-7 Y
ChemSpider 24608641
UNII 81FH7VK1C4
Jmol-3D images Image 1
Properties
Molecular formula C34H34F2N4O6
Molar mass 632.65 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.[2] It is currently in Phase II clinical trials.[3]

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[4]

See also

References

  1. ^ Hedgethorne, K., Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs Fut 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012. 
  2. ^ "XL880 (GSK1363089)". Exelixis, Inc. http://www.exelixis.com/pipeline/xl880. 
  3. ^ "Foretinib". clinicaltrials.gov. http://clinicaltrials.gov/ct2/results?term=Foretinib+. 
  4. ^ Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer research 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.